Contrary to recent data suggesting African-Americans face a higher mortality risk from prostate cancer than Caucasian men, a new study presented at the 2018 American Society for Radiation Oncology (ASTRO) Annual Meeting suggests African-American men may have higher cure rates when treated with radiation therapy than Caucasian men.

Nuclear medicine departments are not communicating proper pre-scan instructions to diabetes mellitus management patients for optimizing fluoride-18 fluorodeoxyglucose (FDG) PET/CT imaging, according to new research published in the Journal of the American College of Radiology.

Pairing PET with CT achieved better diagnostic accuracy than temporal artery biopsy (TAB) in patients with newly suspected giant cell arteritis (GCA), according to research presented recently at the 2018 American College of Rheumatology (ACR)/ Association of Reproductive Health Professional (AHRP) meeting in Chicago.

The technique is able to map the structure of small organic molecules, such as pharmaceuticals and hormones, with electron diffraction imaging—commonly used to chart larger proteins, according to a report published Oct. 19 by Science Magazine.

RT package of latest PET/CT scanner offers comprehensive therapy planning solution.

World's first 85cm 64 and 128 slice wide bore CT unit for oncology

STAMFORD, Conn.—FUJIFILM Medical Systems U.S.A., Inc., a leading provider of diagnostic imaging and medical informatics solutions, today introduced the FCT Embrace. Powered by Analogic, the FCT Embrace is the world’s first 85cm wide bore computed tomography (CT) imaging unitwith 64 or 128 slice configurations. Optimized for both oncology and radiology applications, the FCT Embrace, combined with other market-leading oncology solutions, offers enhanced and efficient CT Simulation with radiotherapy treatment planning capabilities. The unveiling at booth #3063 during the 2018 American Society for Radiation Oncology (ASTRO) Annual Meeting marks Fujifilm’s entry into the CT market, expanding its end-to-end diagnostic imaging product portfolio which is recognized for exceptional imaging at low dose.

"Despite the help offered by this classification system, the BI-RADS 3 category includes probably benign lesions whose management has been widely debated in the literature," wrote Chiara Adriana Pistolese, from the department of diagnostic imaging at Tor Vergata University Rome in Italy, and colleagues.